false 0001711754 0001711754 2024-07-19 2024-07-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 19, 2024

 

INMUNE BIO INC.
(Exact name of registrant as specified in charter)

 

Nevada   001-38793   47-5205835
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of incorporation)       Identification No.)

 

225 NE Mizner Blvd., Suite 640

Boca Raton, Florida 33432

(Address of Principal Executive Offices) (Zip Code)

 

(858) 964 3720

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per shares   INMB   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On July 19, 2024, INmune Bio Inc. (the “Company”), held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, each share of the Company’s common stock was entitled to one vote per share. The matters voted upon and the results are set forth below.

 

Proposal One: Election of Directors.

 

Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company’s stockholders and until his or her successor is elected and qualified. A sixth director nominee, Edgardo Baracchini, resigned from the board of directors prior to the vote being finalized.

 

Nominee  Votes For   Votes
Withheld		   Broker
Non-Votes		 
Raymond J. Tesi, MD   9,947,830    516,892    4,069,201 
J. Kelly Ganjei   9,627,979    836,743    4,069,201 
Tim Schroeder   9,908,788    555,934    4,069,201 
Scott Juda, JD   9,950,069    514,653    4,069,201 
Marcia Allen   9,477,214    987,508    4,069,201 

 

Proposal Two: Ratification of Appointment of Independent Auditor.

 

Stockholders approved the ratification of the appointment of Marcum LLP as the Company’s independent auditors for the fiscal year ending December 31, 2024.

 

For  Against  Abstentions  Broker Non-Votes
14,504,668  7,406  21,849  N/A

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMUNE BIO INC.
   
Date: July 19, 2024 By: /s/ David Moss
    David Moss
    Chief Financial Officer

 

2

 

v3.24.2
Cover
Jul. 19, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 19, 2024
Entity File Number 001-38793
Entity Registrant Name INMUNE BIO INC.
Entity Central Index Key 0001711754
Entity Tax Identification Number 47-5205835
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 225 NE Mizner Blvd.
Entity Address, Address Line Two Suite 640
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33432
City Area Code 858
Local Phone Number 964 3720
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per shares
Trading Symbol INMB
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
INmune Bio (NASDAQ:INMB)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas INmune Bio.
INmune Bio (NASDAQ:INMB)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas INmune Bio.